Skip to main content

Search complete. 20 mentions across 11 episodes found for "CD276".

Nov 19, 2026

Chandler ParkHOST
8:19
You have a lot of referrals for small cell.
Tejas PatilGUEST
8:22
Yeah, I mean, I think the things to watch for in this space are going to be where do B7H3 antibody drug conjugates fit in, where do DLL3 antibody drug conjugates fit in.
Tejas PatilGUEST
8:31
You know, one thing that'll be interesting to watch in the coming years is will we finally get to an era where platinum etoposide is no longer necessary because an ADC plus tarlatumab might actually, or some DLL3 T-cell engager might supplant platinum etoposide.
Tejas PatilGUEST
8:48
So I think that's going to be in the horizon, and I'm looking forward to that data.
Chandler ParkHOST
12:07
And then, you know, I'll stay on that line.
Chandler ParkHOST
12:08
I mean, I think another big study that occurred here, I guess, and world long is, you know, this extension of the antibody drug conjugate.
Chandler ParkHOST
12:16
And we had the B7H3, the Taishan 302, which study evaluated tambolutamide pelletecan, a B7H3 directed antibody drug conjugate against topotecan.
Chandler ParkHOST
12:29
Median overall survival was 13.3 versus 9.4. What do you think about, we talked about the ADCs, Tejas, and how it, you know, knock on wood, hopefully kind of replace the platinum etoposide.
Sam FazeliHOST
25:33
I've just come back from ESMO, which is the second biggest oncology conference globally.
Sam FazeliHOST
25:39
ADCs are everywhere, B7H3, CES6, TROP2.
Sam FazeliHOST
25:44
I mean, you name it.
Sam FazeliHOST
25:46
But they all have, of course, part of the issue is not the antibody or the antigen.
Tom Newsom-DavisGUEST
9:12
There were two trials that came out of China presented at the World Lung Conference in Korea about four weeks ago.
Tom Newsom-DavisGUEST
9:18
And they're ADCs against B7H3.
Tom Newsom-DavisGUEST
9:21
B7H3 is expressed on neuroendocrine cells and is expressed on about 70 or 80 percent of them.
Tom Newsom-DavisGUEST
9:27
So it's quite a common marker.
Tom Newsom-DavisGUEST
9:29
And they either gave an ADC, there's two of them, one's called Tampelli and one's called Rizrez.
Tom Newsom-DavisGUEST
10:19
So that makes me think that they are going to be agents that we will commonly use in the second line treatment of small cell.
Tom Newsom-DavisGUEST
10:27
And so that's very interesting.
Tom Newsom-DavisGUEST
10:29
There are also other antibody drug conjugates which are no longer going to be targeting one target like B7H3.
Silke GillisonGUEST
17:38
But
Tom PowlesHOST
17:39
there was some nice B7H3 work as well, I think.
Tom PowlesHOST
17:40
So there was a
Brian RiniHOST
17:40
study with B7H3
Tom PowlesHOST
17:41
topo-1-ADC plus a PD-L1 VEGF-Bi specific from BioNTech.
Tom PowlesHOST
17:59
And that, but it wasn't in prostate cancer, but it was across broad groups of different tumor groups and had a lot of activity.
Tom PowlesHOST
18:09
And there was also another ADC, PSMA, STEEP1, dual target, TOPO1 payload, abv969 in a phase one that shows some really deep responses too so i kind of looked around and felt there were just lots of new exciting things you could do in prostate cancer which weren't targeting the traditional kind of rp taxane access that we've been doing so i thought it was a really cool meeting for that you know
Silke GillisonGUEST
18:38
Yeah, but you know, even last year we have seen the CaliCrane 2, the bispecific T-cell engager, the STIOP is quite far away.
Ian HaydockHOST
5:15
Meals insisted that the Azure One data was stunning.
Ian HaydockHOST
5:19
He also referenced GSK's Hanso Pharma-partnered antibody drug conjugate Rizvitatog-Rezetacan and the Phase 3 Artemis 011 study, investigating the B7H3 targeted drug for osteosarcoma.
Ian HaydockHOST
5:33
Just before ESMO, GSK reported positive results from its global Phase 1B trial of the ADC in extensive-stage small-cell lung cancer.
Ian HaydockHOST
5:43
There was also a positive presentation in the Spanish capital of data on the other ADC that GSK licensed from Hanso, the B7H4 targeted candidate Mosatatug Resetecan.
Petros GrivasGUEST
37:16
And I think the question is, How do we go from here based on this data set, I think is an important one.
Petros GrivasGUEST
37:23
There are other ADCs under development, phase two, phase three trials, targeting TROP2, HER2, B7H3 and other targets.
Petros GrivasGUEST
37:33
And I think that the future is bright.
Petros GrivasGUEST
37:37
and based on the ongoing investigation and builds upon a very exciting present.
Amy HeimbergerGUEST
32:56
But I do think we've got a new constellation of targets that have been emerging.
Amy HeimbergerGUEST
33:00
You know, I think B7H3 is quite an interesting target.
Amy HeimbergerGUEST
33:03
I think there's some new CAR targets that are going after immune markers that I think are quite interesting.
Amy HeimbergerGUEST
33:10
But again, we have to do the hard work.
Valentina BoniSOUNDBITE_SPEAKER
17:50
One is the bispecific antibody.
Valentina BoniSOUNDBITE_SPEAKER
17:53
We have seen the new emerging modalities of bispecific ADC, in particular dual targeting of EGFR with CMAT and B7H3.
Valentina BoniSOUNDBITE_SPEAKER
18:07
But we have seen also the potential role of a new combination of anti-PD1 VGF combining with ADC.
Valentina BoniSOUNDBITE_SPEAKER
18:18
It was presented phase 2 combining LFD with Pumitamide.
Karim FizaziGUEST
30:54
I think they are coming.
Karim FizaziGUEST
30:56
For example, those that are targeting B7H3 are very promising.
Karim FizaziGUEST
31:01
There are many of them being tested or about to be tested in phase 3.
Karim FizaziGUEST
31:08
There are also PSMA-targeted ADCs.
Karim FizaziGUEST
30:54
I think they are coming.
Karim FizaziGUEST
30:56
For example, those that are targeting B7H3 are very promising.
Karim FizaziGUEST
31:02
There are many of them being tested or about to be tested in phase 3.
Karim FizaziGUEST
31:08
There are also PSMA-targeted ADCs.

1 more episode mentions CD276.

Create an account to see the whole feed, search across every transcript, and follow the entities you care about.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.